Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Cota Chief Scientific Officer to Present at the ACCC Annual Meeting & Cancer Center Business Summit


NEW YORK, March 15, 2018 /PRNewswire/ -- Cota Inc., a real-world data and analytics company bridging precision medicine to population health, today announced its chief scientific officer, Stuart Goldberg, M.D., will speak today, Thursday, March 15 at the Association of Community Cancer Centers (ACCC) 44th Annual Meeting and Cancer Center Business Summit in Washington D.C. The event, taking place at the Renaissance Washington, D.C. Downtown Hotel, brings together leading experts to explore innovation in oncology and discuss approaches for navigating business and policy changes in cancer care.

Cota Logo.

Dr. Goldberg will be speaking during a panel titled "Preparing for Commercial Bundles in Oncology," under the policy track. He will provide an overview of how Cota assists practices in preparing for bundle programs and why practices need a complete understanding of the types of patients they see and the associated costs. Cota's precise disease classification system, the Cota Nodal Addresstm (CNA), is the market leader in facilitating commercial bundle design. It considers differences in patients with cancer and breaks them into smaller cohorts of similar patients, thus facilitating bundle design. Representatives from Horizon Blue Cross Blue Shield of New Jersey and Archway Health will also be speaking on the panel.

Cota's CNA is a breakthrough method of precisely classifying patients and their diseases using a concise digital code to enable innovation in precision medicine. The patented system organizes the complexities of patients and their diseases in a form that permits detailed analysis of outcomes, toxicities, practice patterns, care variances and cost. It then assesses these factors to build a bundled program where the provider understands the average costs and where savings can be made.

For those interested in attending Dr. Goldberg's presentation, please refer to the following information:

For more information or to schedule a meeting with Cota representatives at the event, please reach out to Cota via [email protected].

About Cota 
Cota is a real-world data and analytics company that enables providers, payers and life science companies involved in diagnosing and treating complex diseases to optimize the outcomes of individual patients and lower the overall cost of the patient population served. It is powered by the patented Cota Nodal Addresstm (CNA) system, a unique digital classification methodology built by leading physicians and data scientists. The CNA is the first and only system that precisely categorizes patient factors, their diseases and intended therapies, enabling precision medicine at scale.

Cota's technology enriches medical records to create research-grade data and joins it with a suite of analysis, visualization and management tools. This enables providers, payers and life science companies to analyze, report on and research outcomes, costs, treatments and quality at any granularity and stage of the patient journey. The result is a constantly improving system that merges technology and medicine to improve the lives of patients everywhere. For more information, go to www.cotahealthcare.com

Alessandra Nix
SHIFT Communications
[email protected]   
617.779.1860

 

SOURCE Cota


These press releases may also interest you

at 10:10
HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical...

at 10:10
Bicycle Therapeutics plc , a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation...

at 10:07
W.W. Grainger, Inc. announced today that its board of directors approved a quarterly cash dividend of $2.05 per share, an increase of 10% from the most recent company dividend. The dividend is payable on June 1, 2024, to shareholders of record on...

at 10:05
Udemy , a leading online skills marketplace and learning platform, today released its Q1 2024 Global Workplace Learning Index, a quarterly report highlighting in-demand skills that help companies remain competitive in a fast-changing global economy....

at 10:05
RouteSmart Technologies will be unveiling RouteSmart for ArcGIS Pro, a revolutionary solution designed to transform snowplow operations, at the APWA North American Snow Show. This advanced solution leverages sophisticated algorithms to address the...

at 10:05
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced two presentations, including an oral presentation on the Phase 1 first-in-human study of OBX-115, a novel engineered...



News published on and distributed by: